{"filing":{"accession_number":"0001193125-26-292501","cik":"0001001233","ticker":"SGMO","company_name":"SANGAMO THERAPEUTICS, INC","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"d113173d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526292501/d113173d8k.htm"},"events":[{"id":15448,"run_id":13779,"accession_number":"0001193125-26-292501","anchor_item_number":"8.01","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Sangamo Therapeutics filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code, with the company's common stock beginning trading on the OTC Basic Market on June 24, 2026 as a result of the bankruptcy filing.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13219,"accession_number":"0001193125-26-292501","item_number":"8.01","item_title":"Other Events.","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Sangamo Therapeutics filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code, with the company's common stock beginning trading on the OTC Basic Market on June 24, 2026 as a result. This is a terminal event — a Chapter 11 bankruptcy filing — that materially threatens the registrant's continued existence and is the most salient disclosure in this section.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:03:01.942664+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":15449,"run_id":13779,"accession_number":"0001193125-26-292501","anchor_item_number":"4.01","event_type":"auditor_change","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"The Audit Committee terminated Ernst \u0026 Young LLP as the Company's independent registered public accounting firm on June 25, 2026, following the Company's Chapter 11 bankruptcy filing.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13218,"accession_number":"0001193125-26-292501","item_number":"4.01","item_title":"Change in Registrant’s Certifying Accountant.","event_type":"auditor_change","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"The Audit Committee terminated Ernst \u0026 Young LLP as the Company's independent registered public accounting firm on June 25, 2026, following the Company's Chapter 11 bankruptcy filing. This is a clear auditor change under Item 4.01. The materiality is heightened by the bankruptcy context and the going-concern warnings in EY's prior audit reports, making this disclosure material to investors assessing the registrant's financial condition and audit independence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:03:01.942664+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13218,"accession_number":"0001193125-26-292501","item_number":"4.01","item_title":"Change in Registrant’s Certifying Accountant.","event_type":"auditor_change","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"The Audit Committee terminated Ernst \u0026 Young LLP as the Company's independent registered public accounting firm on June 25, 2026, following the Company's Chapter 11 bankruptcy filing. This is a clear auditor change under Item 4.01. The materiality is heightened by the bankruptcy context and the going-concern warnings in EY's prior audit reports, making this disclosure material to investors assessing the registrant's financial condition and audit independence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:03:01.942664+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-07-01"},{"id":13219,"accession_number":"0001193125-26-292501","item_number":"8.01","item_title":"Other Events.","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Sangamo Therapeutics filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code, with the company's common stock beginning trading on the OTC Basic Market on June 24, 2026 as a result. This is a terminal event — a Chapter 11 bankruptcy filing — that materially threatens the registrant's continued existence and is the most salient disclosure in this section.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:03:01.942664+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-07-01"}]}